Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 251

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 251
---
000 |     |   4.3 |   |
| Parent(7)                                  |     |     28,500,000 |     |  80.9 |   |     |    28,500,000 |     |  80.8 |   |     |    28,500,000 |     |  80.7 |   |
| Theo(8)                                    |     |        396,531 |     |   1.1 |   |     |       698,266 |     |   2.0 |   |     |     1,000,000 |     |   2.8 |   |
| Total                                      |     |     35,229,087 |     | 100.0 | % |     |    35,270,794 |     | 100.0 | % |     |    35,312,500 |     | 100.0 | % |

____________ Notes:- (1)Assumes that no Public Shares are redeemed. (2)Assumes that 260,028 Public Shares are redeemed. (3)Assumes that all 520,056 Public Shares are redeemed. (4)Corresponds to 3,342,188 Company Shares to be issued to Sponsor. (5)Corresponds to 970,312 Company Shares to be issued to the Initial Sponsor. (6)The number of shares corresponding to the Public Shareholders includes the effects of redemptions after June 30, 2024, described in footnote (1) under “ Adjustments to Unaudited Pro Forma Combined Consolidated Statement of Financial Position as of June 30, 2024.” (7)Prior to Closing, the Parent expects to redeem a portion of the Parent shares held by Theo, and Theo expects to subsequently distribute a total of 1,500,000 Company Shares to between 300 and 424shareholders of Bioceres S.A. and Bioceres Group so that the Company will comply with Nasdaq listing requirements. (8)Company Shares issued to Theo pursuant to the Backstop Agreement assuming that it satisfies its obligations thereunder pursuant to the subscription of up to 1,000,000 Company Shares at an issue price of $10.00 per Company Share (par value of $0.0001) and making a cash contribution in an amount of up to $10,000,000 that exceeds the aggregate amount of cash on deposit in